Prostatype[®] shows strong data in Asian pilot study
-Selected for presentation at the Chinese Urology Association’s national congress With the second independent pilot study in the East Asia region showing strong clinical performance, Prostatype Genomics is now reviewing commercialization opportunities in the region.The recent study was conducted in China in collaboration with the Nanjing Drum Tower University Hospital, Jiangsu, and Prostatype Genomics’ partner GloriousMed based in Shanghai. The study indicates that the clinical performance of Prostatype® in East Asian population is in line with the results previously communicated results